Skip to content

Study · Randomized controlled trial · n = 52 · 2023

6 results

Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility.

Nerild HH, Brønden A, Gether IM, Hellmann PH, Baekdal M, Gillum MP, Svenningsen JS, Hartmann B, Rathor N, Kudiyanur Muniraju HA, Rehfeld JF, Holst JJ, Vilsbøll T, Sonne DP, Knop FK

Diabetes, obesity & metabolism13 Mar 2023Cited by 11 (Europe PMC)

PMID36781820 (opens in a new tab)DOI10.1111/dom.15017 (opens in a new tab)PepBankPUB-36781820
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In adults with obesity, liraglutide reduced postprandial FGF19 versus placebo after the first dose (treatment ratio 0.52).

    In plain wordsIn adults with obesity, liraglutide lowered the after-meal rise of the gut hormone FGF19 compared with placebo after the first dose.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial FGF19 after first dose
    Study

    n = 52

    Comparator
    Placebo
    Outcome group
    Hormone levels · Gastrointestinal
    Studied dose
    0.6 mg escalated to 3.0 mg once daily · subcutaneous · first doseAs given in this study (human).

    Measurements

    Treatment ratio
    0.52
    FGF19 AUC, first dose

    Source sentences

    Summary
    Liraglutide reduced postprandial FGF19 after the first dose [area under the curve (AUC)0-240 min 24.8 vs. 48.0 min × ng/ml, treatment ratio (TR) (95% confidence interval) 0.52 (0.39; 0.69)]
    1 context sentence
    Summary · context
    In a double-blind, 12-week trial, 52 participants [50% male, age 47.6 ± 10.0 years, body mass index 32.6 ± 3.4 kg/m2 (mean ± standard deviation)] with obesity were randomized 1:1 to once-daily subcutaneous liraglutide (escalated from 0.6 mg to 3.0 mg once-daily) or placebo.
  2. 02HumanRandomized controlled trialMechanism

    In adults with obesity, liraglutide reduced postprandial FGF19 versus placebo after 12 weeks (treatment ratio 0.69).

    In plain wordsIn adults with obesity, liraglutide lowered the after-meal rise of the gut hormone FGF19 compared with placebo after 12 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial FGF19 after 12 weeks
    Study

    n = 52

    Comparator
    Placebo
    Outcome group
    Hormone levels · Gastrointestinal
    Studied dose
    0.6 mg escalated to 3.0 mg once daily · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Treatment ratio
    0.69
    FGF19 AUC, 12 weeks

    Source sentences

    Summary
    following 12 weeks of treatment [AUC0-240 min 33.7 vs. 48.5 ng/ml × min, TR 0.69 (0.52; 0.93)]
    1 context sentence
    Summary · context
    In a double-blind, 12-week trial, 52 participants [50% male, age 47.6 ± 10.0 years, body mass index 32.6 ± 3.4 kg/m2 (mean ± standard deviation)] with obesity were randomized 1:1 to once-daily subcutaneous liraglutide (escalated from 0.6 mg to 3.0 mg once-daily) or placebo.
  3. 03HumanRandomized controlled trialMechanism

    In adults with obesity, liraglutide reduced postprandial GLP-2 versus placebo after the first dose (treatment ratio 0.75).

    In plain wordsIn adults with obesity, liraglutide lowered the after-meal rise of the gut hormone GLP-2 compared with placebo after the first dose.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial GLP-2 after first dose
    Study

    n = 52

    Comparator
    Placebo
    Outcome group
    Hormone levels · Gastrointestinal
    Studied dose
    0.6 mg escalated to 3.0 mg once daily · subcutaneous · first doseAs given in this study (human).

    Measurements

    Treatment ratio
    0.75
    GLP-2 AUC, first dose

    Source sentences

    Summary
    Liraglutide also reduced postprandial GLP-2 responses (AUC0-240 min 3650 vs. 4894 min × pmol/L, TR 0.75 (0.62; 0.90)]
    1 context sentence
    Summary · context
    In a double-blind, 12-week trial, 52 participants [50% male, age 47.6 ± 10.0 years, body mass index 32.6 ± 3.4 kg/m2 (mean ± standard deviation)] with obesity were randomized 1:1 to once-daily subcutaneous liraglutide (escalated from 0.6 mg to 3.0 mg once-daily) or placebo.
  4. 04HumanRandomized controlled trialMechanism

    In adults with obesity, liraglutide reduced postprandial GLP-2 versus placebo after 12 weeks (treatment ratio 0.77).

    In plain wordsIn adults with obesity, liraglutide lowered the after-meal rise of the gut hormone GLP-2 compared with placebo after 12 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial GLP-2 after 12 weeks
    Study

    n = 52

    Comparator
    Placebo
    Outcome group
    Hormone levels · Gastrointestinal
    Studied dose
    0.6 mg escalated to 3.0 mg once daily · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Treatment ratio
    0.77
    GLP-2 AUC, 12 weeks

    Source sentences

    Summary
    as well as after 12 weeks [AUC0-240 min 3760 vs. 4882 min × pmol/L, TR 0.77 (0.60; 0.99)]
    1 context sentence
    Summary · context
    In a double-blind, 12-week trial, 52 participants [50% male, age 47.6 ± 10.0 years, body mass index 32.6 ± 3.4 kg/m2 (mean ± standard deviation)] with obesity were randomized 1:1 to once-daily subcutaneous liraglutide (escalated from 0.6 mg to 3.0 mg once-daily) or placebo.
  5. 05HumanRandomized controlled trialMechanism

    In adults with obesity, the postprandial CCK response after the first dose of liraglutide was numerically higher than with placebo (treatment ratio 1.14), with a confidence interval that includes 1.

    In plain wordsIn adults with obesity, the after-meal CCK response after the first liraglutide dose was not clearly different from placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changePostprandial CCK after first dose
    Study

    n = 52

    Comparator
    Placebo
    Outcome group
    Hormone levels · Gastrointestinal
    Studied dose
    0.6 mg escalated to 3.0 mg once daily · subcutaneous · first doseAs given in this study (human).

    Measurements

    Treatment ratio
    1.14
    CCK AUC, first dose

    Source sentences

    Summary
    Liraglutide increased postprandial responses of CCK after the first dose [AUC0-240 min 762 vs. 670 min × pmol/L; TR 1.14 (0.97; 1.33)]
    1 context sentence
    Summary · context
    In a double-blind, 12-week trial, 52 participants [50% male, age 47.6 ± 10.0 years, body mass index 32.6 ± 3.4 kg/m2 (mean ± standard deviation)] with obesity were randomized 1:1 to once-daily subcutaneous liraglutide (escalated from 0.6 mg to 3.0 mg once-daily) or placebo.
  6. 06HumanRandomized controlled trialMechanism

    In adults with obesity, liraglutide increased postprandial CCK versus placebo after 12 weeks (treatment ratio 1.39).

    In plain wordsIn adults with obesity, liraglutide raised the after-meal rise of the gut hormone CCK compared with placebo after 12 weeks.

    Peptide
    Liraglutide
    Outcome
    IncreasePostprandial CCK after 12 weeks
    Study

    n = 52

    Comparator
    Placebo
    Outcome group
    Hormone levels · Gastrointestinal
    Studied dose
    0.6 mg escalated to 3.0 mg once daily · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Treatment ratio
    1.39
    CCK AUC, 12 weeks

    Source sentences

    Summary
    following 12 weeks of treatment [AUC0-240 min 873 vs. 628 min × pmol/L; TR 1.39 (1.12; 1.73)]
    1 context sentence
    Summary · context
    In a double-blind, 12-week trial, 52 participants [50% male, age 47.6 ± 10.0 years, body mass index 32.6 ± 3.4 kg/m2 (mean ± standard deviation)] with obesity were randomized 1:1 to once-daily subcutaneous liraglutide (escalated from 0.6 mg to 3.0 mg once-daily) or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.